Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiple BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma.

JAMA dermatology - 1 May 2015

Carrera Cristina, Puig-Butillè Joan A, Tell-Marti Gemma, García Adriana, Badenas Celia, Alós Llucia, Puig Susana, Malvehy Josep

Abstract excerpt

IMPORTANCE: BRAF inhibitors have become the standard of care in metastatic BRAF-mutant melanomas. Compared with chemotherapies, BRAF inhibitors improve overall and disease-free survival and speed the recovery of symptomatic patients with metastatic disease. The most worrisome finding is the possible development of resistance to new malignant tumors. OBSERVATIONS: A patient in her 30s developed massive BRAFV600E...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cesarean Section
Share to Fatal Outcome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Live Birth

Share to Melanoma, Cutaneous Malignant

Share to Neoplasms, Multiple Primary

Share to Oximes

Share to Pregnancy Complications, Neoplastic

Source

Identifiers

PMID: 25651238
DOI: 10.1001/jamadermatol.2014.4115

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiple BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma.PMID 25651238Read ↗

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.Semantic proximity Read ↗

Dabrafenib for the treatment of melanoma.Semantic proximity Read ↗

Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.Semantic proximity Read ↗

Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.Semantic proximity Read ↗

Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma.Semantic proximity Read ↗

[Unusual association of BRAF and MEK inhibitors: Clinical response of metastatic melanoma treated with dabrafenib-cobimetinib].Semantic proximity Read ↗

Successful rechallenge therapy for BRAF/MEK inhibitor-resistant multiple brain metastases of melanoma.Semantic proximity Read ↗

Partial response of metastatic melanoma to BRAF-inhibitor-monotherapy in a pregnant patient with no fetal toxicitySemantic proximity Read ↗

Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma.Semantic proximity Read ↗

Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment.Semantic proximity Read ↗

Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset.Semantic proximity Read ↗

Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.